Novartis AG (NVS) Balance Sheet

The balance sheet is expanding rapidly, driven primarily by debt-funded acquisitions, as evidenced by the $12B acquisition cash outflow in 2026Q1 per cash flow statements. While asset growth signals strategic investment, the concurrent rise in leverage from 0.69 to 1.17 D/E over ten quarters suggests a deliberate shift toward a more leveraged capital structure. This trajectory may indicate management's confidence in future cash flows, but it also increases financial risk, especially if revenue growth continues to decelerate as seen in the income statement.

The debt increase appears strategic, likely funding acquisitions and share buybacks, but it has elevated leverage to levels that exceed most large pharma peers. With a current ratio of 0.86, short-term obligations exceed liquid assets, suggesting reliance on refinancing or operating cash flows to meet near-term liabilities. Investors should monitor refinancing risk, especially if interest rates remain elevated, as the company's cash position of $7.6B covers only a fraction of total debt.

The asset mix is increasingly dominated by goodwill and intangibles from M&A, which now constitute a significant portion of total assets. This suggests that organic growth is being supplemented by acquisitions, but it also raises impairment risk if acquired businesses underperform. The relatively low PPE of $12.3B underscores the asset-light nature of pharma manufacturing, but the growing goodwill balance warrants close monitoring for potential write-downs.

The decline in equity, despite positive retained earnings, indicates that capital returns and acquisition costs are outpacing earnings retention. This suggests that the company is prioritizing shareholder returns and growth investments over balance sheet strength. The equity base remains substantial, but the rising D/E ratio implies that creditors are bearing more risk, which could pressure credit ratings and increase future financing costs.

The deterioration in the current ratio below 1.0 suggests that current liabilities now exceed current assets, a potential red flag for short-term solvency. However, given the company's strong operating cash flow (averaging over $4.6B per quarter per cash flow statements), the liquidity squeeze may be temporary. Still, the reduced cash buffer and high debt levels could limit flexibility to weather unexpected shocks or fund further acquisitions without additional borrowing.